Tilray’s Mixed Quarter: Record Revenue Amid Segment Struggles
07.02.2026 - 10:47:04
Tilray Brands has reported its highest-ever quarterly revenue for the second fiscal quarter of 2026, alongside a significant reduction in net loss. However, the company's latest financial results reveal a tale of two businesses: its pharmaceutical and cannabis divisions are surging ahead, while its beverage segment is acting as a notable drag on performance.
The company's overall financial picture demonstrated marked improvement. Tilray succeeded in nearly halving its net loss, which fell to $43.5 million from $85.3 million in the prior-year period. This progress is supported by a strong liquidity position of $292 million and a reaffirmed EBITDA outlook for the full fiscal year, indicating underlying financial stability.
A Closer Look at the Divergence
The record net revenue of $217.5 million, representing a 3% year-over-year increase, was driven by specific high-performing units. The international medical cannabis business was a standout, posting impressive growth of 36%. Operational efficiencies also boosted the gross margin within the cannabis segment to 39%.
Simultaneously, the distribution business, which includes CC Pharma, achieved a historic milestone with quarterly revenue of $85.3 million. In a related development announced Wednesday, CC Pharma received a Top Innovator award in Germany, highlighting the strategic importance of the German market to Tilray's European expansion strategy.
Should investors sell immediately? Or is it worth buying Tilray?
Beverage Unit Presents a Challenge
In contrast, the beverage division's performance was a clear weak spot, tempering the positive overall results. Revenue for this segment declined substantially to $50.1 million from $63.1 million a year ago. Profitability also suffered, with the gross margin contracting from 40% to 31%.
Management is actively pursuing strategies to reverse this trend. On February 4th, the company revealed a new partnership with Romano Beverage, aimed at strengthening the distribution of its Breckenridge Distillery brand in the state of Illinois.
The Path Forward
While Tilray's latest earnings report, released on January 8th, shows commendable progress on profitability and top-line growth, the path ahead involves addressing the volatility within its beverage operations. The company's ability to stabilize this segment will be crucial for sustaining its momentum toward consistent profitability.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from February 7 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Tilray: Buy or sell? Read more here...
